EGFR and non-small cell lung carcinoma: HDACis combined with EGFR-TKIs effectively overcomes TKIs resistance.439–441 For example, the combination of vorinostat and osimertinib attenuates apoptosis resistance in NSCLC cell lines with BIM deletion polymorphisms.442 The combination of vorinostat and brigatinib has been effective in LUAD cell lines with third-generation EGFR-TKIs resistance mutations.443 Epigenetic regulatory interventions are diverse, but it is clear that epigenetic manipulation is an effective strategy to restore TKI sensitivity.444,445